Gender-related differences in the efficacy and safety of ritonavir-boosted tipranavir [tipranavir/ritonavir (TPV/r) 500/200 mg twice daily (b.i.d.)] were evaluated in a subanalysis of the Randomized Evaluation of Strategic Intervention in Multidrug Resistant Patients with Tipranavir (RESIST) trials. Data from HIV-1-infected women (203; TPV/r = 117) and men (1280; TPV/r = 629) showed no significant gender-related differences in HIV RNA response rates (at 48 weeks) and safety (at 96 weeks) despite higher mean steady-state plasma TPV trough concentrations in women. Significantly greater increases in CD4 cell count (+81.2 vs. +48.6; P = 0.0012) were observed in women at week 48.
aUniversity Health Network, University of Toronto, Toronto, Canada
bJefferson Medical College of Thomas Jefferson University, Philadelphia, Pennsylvania, USA
cUniversité Paris Descartes, Faculté de Médecine; AP-HP, Hôpital Européen Georges Pompidou, Paris, France
dKing's College Hospital, London, UK
eClinica di Malattie Infective, Lecco, Italy
fBoehringer Ingelheim, Ingelheim, Germany.
Received 8 October, 2008
Accepted 27 October, 2008
Correspondence to Sharon Walmsley, Professor of Medicine, University Health Network, Eaton North Wing, 13th floor Rm. 218, 200 Elizabeth Street, Toronto, Ontario, Canada M5G 2C4. E-mail: firstname.lastname@example.org